LY4170156 for Ovarian Cancer

(FRAmework-01 Trial)

This trial explores a new medicine, LY4170156, for treating specific ovarian, peritoneal, and fallopian tube cancers. It aims to determine if this treatment works better and is safer than current options. The trial consists of two parts: one for cancers that no longer respond to platinum-based chemotherapy and another for those that still do. People whose cancer has progressed after previous treatments and who have certain types of ovarian cancer might be suitable candidates. Participants will receive treatments through an IV, and their continued involvement will depend on their response to the treatment. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that LY4170156 is well-tolerated by patients with advanced solid tumors. These studies have yielded promising results, with patients generally managing the treatment well, even those with extensive prior treatments.

When combined with Bevacizumab, the safety results for LY4170156 remain encouraging. Bevacizumab, already used to treat ovarian cancer, has been extensively studied. Patients have generally tolerated it well in real-world settings, though individual experiences may vary.

Unlike the standard treatments for ovarian cancer, which often involve chemotherapy or targeted therapies like Mirvetuximab Soravtansine, LY4170156 is unique because it is an investigational drug with a potentially new mechanism of action. Researchers are particularly excited about LY4170156 due to its novel approach when combined with Bevacizumab, a well-known angiogenesis inhibitor, which might enhance its effectiveness against ovarian tumors. This combination could offer new hope for patients by potentially improving outcomes beyond what current standard therapies achieve.

Research has shown that LY4170156 may help treat ovarian cancer. Early studies found that LY4170156 could stop tumor growth in various lab models, even when other treatments, like mirvetuximab soravtansine, were ineffective. In this trial, some participants will receive LY4170156 alone, while others will receive it with Bevacizumab. A study with patients who had solid tumors, including ovarian cancer, showed that LY4170156 provided a clinical benefit to 56% of participants, meaning more than half experienced positive effects. Additionally, when combined with Bevacizumab, LY4170156 appeared to improve treatment results, although detailed results in humans remain limited. These findings suggest LY4170156 might be effective for certain types of ovarian cancer, especially when standard treatments fail.¹²⁶⁷⁸